CYP2D6 polymorphism: Implications for antipsychotic drug response, schizophrenia and personality traits

Pharmacogenomics

Volumn 8, Issue 11, 2007, Pages 1597-1608

  Dorado, Pedro ^a   Peñas Lledó, Eva M ^a   LLerena, Adrián ^a,b  

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b UNIVERSITY OF BEIRA INTERIOR   (Portugal)

Author keywords

Adverse side effects; Antipsychotics; CYP2D6; Personality; Pharmacogenetics; Pharmacogenomics; QTc; Schizophrenia; Vulnerability

Indexed keywords

5 METHOXYTRYPTAMINE; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; CYTOCHROME P450 2D6; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; NEUROTRANSMITTER; NORCLOZAPINE; OLANZAPINE; PAROXETINE; PERPHENAZINE; PHENOTHIAZINE; QUETIAPINE; RISPERIDONE; SEROTONIN RECEPTOR; THIORIDAZINE; ZUCLOPENTHIXOL;

AKATHISIA; ALLELE; ANXIETY DISORDER; AUTONOMIC DYSFUNCTION; BRAIN CORTEX; CARDIOTOXICITY; CASE CONTROL STUDY; CENTRAL NERVOUS SYSTEM DISEASE; CEREBELLUM; DIABETES MELLITUS; DOPAMINERGIC ACTIVITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DYSTONIA; ENZYME ACTIVITY; ENZYME METABOLISM; EXTRAPYRAMIDAL SYMPTOM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HIPPOCAMPUS; HUMAN; MONOTHERAPY; MOTOR DYSFUNCTION; NEUROLEPTIC MALIGNANT SYNDROME; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PERSONALITY DISORDER; PHARMACOGENETICS; PROTEIN SYNTHESIS INHIBITION; PSYCHOSIS; QT PROLONGATION; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SOCIAL PHOBIA; SOMNOLENCE; TARDIVE DYSKINESIA; VOLUNTEER; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 CYP2D6; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PERSONALITY; POLYMORPHISM, GENETIC; SCHIZOPHRENIA;

EID: 37349090515     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.11.1597     Document Type: Review

References (89)

1. Dorado P, Berecz R, Penas-Lledo EM, Caceres MC, LLerena A: Clinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic: drugs. Curr. Drug Targets 7 671-680 (2006).
2. Yu AM, Idle JR, Gonzalez FJ: Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates. Drug Metab. Rev. 36, 243-277 (2004).
3. Miksys SL, Tyndale RF: Drug-metabolizing cytochrome P450s in the brain. J. Psychiatry Neurosci., 27, 406-415 (2002).
4. Schultz SK, Andreasen NC: Schizophrenia. Lancet 353, 1425-1430 (1999).
5. LLerena A, de la Rubia A, Penas-Lledo EM, Diaz FJ, de Leon J: Schizophrenia and tobacco smoking in a Spanish psychiatric hospital. Schizophr. Res. 60, 313-317 (2003).
6. Berecz R, de la Rubia A, Dorado P, Fernandez-Salguero P, Dahl ML, LLerena A: Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. Eur. J. Clin. Pharmacol. 59, 45-50 (2003).
7. Miksys S, Tyndale RF: Nicotine induces brain CYP enzymes: relevance to Parkinson's disease. J Neural. Transm. (Suppl.) 70, 177-180 (2006).
8. Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S: CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet. Genomics 17, 93-101 (2007).
9. Bradford LD: CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3, 229-243 (2002).
10. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjoqvist F, Ingelman-Sundberg M: Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol. Pharmacol. 46, 452-459 (1994).
11. Masimirembwa C, Persson I, Bertilsson L, Hasler J, Ingelman-Sundberg M: A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. Br. J. Clin. Pharmacol. 42, 713-719 (1996).
12. Bertilsson L, Dahl ML, Ekqvist B, Llerena A: Disposition of the neuroleptics perphenazine, zuclopenthixol, and haloperidol cosegregates with polymorphic debrisoquine hydroxylation. Psychopharmacol. Ser. 10, 230-237 (1993).
13. Gaedigk A, Ndjountche L, Divakaran K et al.: Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: characterization of gene duplication events. Clin. Pharmacol. Ther. 81, 242-251 (2007).
14. Dorado P, Peñas-LLedó EM, Cáceres MC, LLerena A: Multiplication of CYP2D6 non active alleles: controversy about the high frequency of ultrapids in south-Europeans. Basic Clin. Pharmacol. Toxicol. 101 (Suppl. 1), 51-102 (2007).
15. LLerena A, Dorado P, Penas-Lledo EM, Caceres MC, De la Rubia A: Low frequency of CYP2D6 poor metabolizers among schizophrenia patients. Pharmacogenomics J. (2007) (Epub ahead of print).
16. Dorado P, Berecz R, Caceres MC, Gonzalez I, Cobaleda J, Llerena A: Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship. Clin. Chem. Lab. Med. 43, 275-279 (2005).
17. Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjoqvist F: Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol. Exp. Ther. 274, 516-520 (1995).
18. LLerena A, Cobaleda J, Benitez J: Debrisoquine hydroxylation phenotypes in healthy volunteers. Lancet 1, 1398 (1989).
19. Bertilsson L, Alm C, De Las Carreras C, Widen J, Edman G, Schalling D: Debrisoquine hydroxylation polymorphism, and personality. Lancet 1, 555 (1989).
20. Schalling D, Asberg M, Edman G, Oreland L: Markers for vulnerability to psychopathology: temperament traits associated with platelet MAO activity. Acta Psychiatr. Scand. 76, 172-182 (1987).
21. LLerena A, Edman G, Cobaleda J, Benitez J, Schalling D, Bertilsson L: Relationship between personality and debrisoquine hydroxylation capacity Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psychiatr. Scand. 87, 23-28 (1993).
22. González I, Peñas-LLedó EM, Pérez B, Dorado P, Álvarez M, LLerena A: The relation between CYP2D6 pheno- and genotype and personality in healthy volunteers. Basic Clin. Pharmacol. Toxicol. 101(Suppl. 1), 51-102 (2007).
23. Ortet G, Ibáñez M, LLerena A, Torrubia R: The underlying traits of the Karolinska Scales of Personality (KSP). Eur. J. Psychologic. Asses. 18, 139-148 (2002).
24. Gan SH, Ismail R, Wan Adnan WA, Zulmi W, Kumaraswamy N, Larmie ET: Relationship between Type A and B personality and debrisoquine hydroxylation capacity. Br. J. Clin. Pharmacol. 57, 785-789 (2004).
25. Roberts RL, Luty SE, Mulder RT, Joyce PR, Kennedy MA: Association between cytochrome P450 2D6 genotype and harm avoidance. Am. J. Med. Genet. B NeuroPsychiatr. Genet. 127, 90-93 (2004).
26. Kirchheiner J, Lang U, Stamm T, Sander T, Gallinat J: Association of CYP2D6 genotypes and personality traits in healthy individuals. J. Clin. Psychopharmacol. 26, 440-442 (2006).
27. Hiroi T, Imaoka S, Funae Y: Dopamine formation from tyramine by CYP2D6. Biochem. Biophys. Res. Commun. 249, 838-843 (1998).
28. Kirchheiner J, Henckel HB, Franke L et al.: Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets. Pharmacogenet. Genomics 15, 579-587 (2005).
29. Ozdemir V, Gunes A, Dahl ML, Scordo MG, Williams-Jones B, Someya T: Could endogenous substrates of drug-metabolizing enzymes influence constitutive physiology and drug target responsiveness? Pharmacogenomics 7, 1199-1210 (2006).
30. Ozdemir V, Bertilsson L, Miura J et al.: CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk revisited. Pharmacogenet Genomics 17, 339-347 (2007).
31. Alex KD, Pehek EA: Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol. Ther. 113, 296-320 (2007).
32. Frankle WG, Lombardo I, New AS et al.: Brain serotonin transporter distribution in subjects with impulsive aggressivity: a positron emission study with [11C]McN 5652. Am. J. Psychiatry 162, 915-923 (2002).
33. Carli M, Baviera M, Invernizzi RW, Balducci C: Dissociable contribution of 5-HT1A and 5-HT2A receptors in the medial prefrontal cortex to different aspects of executive control such as impulsivity and compulsive perseveration in rats. NeuroPsychopharmacology 31, 757-767 (2006).
34. Niwa T, Hiroi T, Tsuzuki D et al.: Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res. Mol. Brain Res. 129, 117-123 (2004).
35. Hiroi T, Kishimoto W, Chow T, Imaoka S, Igarashi T, Funae Y: Progesterone oxidation by cytochrome P450 2D isoforms in the brain. Endocrinology 142, 3901-3908 (2001).
36. Willner P: The dopamine hypothesis of schizophrenia: current status, future prospects. Int. Clin. Psychopharmacol. 12, 297-308 (1997).
37. Burnet PW, Eastwood SL, Harrison PJ: 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. NeuroPsychopharmacology 15, 442-455 (1996).
38. Burnet PW, Eastwood SL, Harrison PJ: [3H]WAY-100635 for 5-HT1A receptor autoradiography in human brain: a comparison with [3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia. Neurochem. Int. 30, 565-574 (1997).
39. East SZ, Burnet PW, Kerwin RW, Harrison PJ: An RT-PCR study of 5-HT(6) and 5-HT(7) receptor mRNAs in the hippocampal formation and prefrontal cortex in schizophrenia. Schizophr. Res. 57, 15-26 (2002).
40. Peñas-LLedó EM, Dorado P, Cáceres MC, de la Rubia A, LLerena A: Association between T102C and A-1438G polymorphisms in serotonin receptor 2A (5-HT2A) gene and schizophrenia: relevance for treatment with antipsychotic drugs. Clin. Chem. Lab. Med. 45, 835-838 (2007).
41. Horacek J, Bubenikova-Valesova V, Kopecek M et al.: Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 20, 389-409 (2006).
42. Dahl AA, Lowert A, Asserson S et al.: Hydroxylation polymorphism of debrisoquine hydroxylase (CYP2D6) in patients with schizophrenia in Norway and Denmark. Hum. Psychopharmacol. 13, 509-511 (1998).
43. Brockmoller J, Kirchheiner J, Schmider J et al.: The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin. Pharmacol. Ther 72, 438-452 (2002).
44. Dawson E, Powell JF, Nothen MM et al.: An association study of debrisoquine, hydroxylase (CYP2D6) polymorphisms in schizophrenia. Psychiatr. Genet. 4, 215-218 (1994).
45. Daniels J, Williams J, Asherson P. McGuffin P, Owen M: No association between schizophrenia and polymorphisms within the genes for debrisoquine 4-hydroxylase (CYP2D6) and the dopamine transporter (DAT). Am. J. Med. Genet. 60, 85-87 (1995).
46. Pirmohamed M, Wild MJ, Kitteringham NR et al.: Lack association between schizophrenia and the CYP2D6 gene polymorphisms. Am. J. Med. Genet. 67, 236-237 (1996).
47. Jonsson EG, Dahl ML, Rob HK, Jerling M, Sedvall GC: Lack of association between debrisoquine 4-hydroxylase (CYP2D6) gene polymorphisms and schizophrenia. Psychiatr. Genet. 8, 25-28 (1998).
48. Chen CH, Hung CC, Wei FC, Koong FJ: Debrisoquine 4-hydroxylase (CYP2D6) genetic polymorphisms and susceptibility to schizophrenia in Chinese patients from Taiwan. Psychiatr. Genet. 11, 153-155 (2001).
49. Dahl ML: Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin. Pharmacokinet. 41, 453-470 (2002).
50. Kubo M, Koue T, Inaba A et al.: Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic aripiprazole. Drug Metab. Pharmacokinet. 20, 55-64 (2005).
51. Hendset M, Hermann M, Lunde H, Refsum H, Molden E: Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole. Eur. J. Clin. Pharmacol. (2007) (Epub ahead of print).
52. Spina E, Martines C, Caputi AP et al.: Debrisoquine oxidation phenotype during neuroleptic monotherapy. Eur. J. Clin. Pharmacol. 41, 467-470 (1991).
53. Suzuki Y, Someya T, Shimoda K et al.: Importance of the cytochrome P450 2D6 genotype for the drug metabolic interaction between chlorpromazine and haloperidol. Ther. Drug Monit. 23, 363-368 (2001).
54. Bertilsson L, Carrillo JA, Dahl ML et al.: Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br. J. Clin. Pharmacol. 38, 471-473 (1994).
55. Dahl ML, Llerena A, Bondesson U, Lindstrom L, Bertilsson L: Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. Br. J. Clin. Pharmacol. 37, 71-74 (1994).
56. Spina E, Avenoso A, Salemi M et al.: Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline. Pharmacopsychiatry 33, 213-217 (2000).
57. LLerena A, Herraiz AG, Cobaleda J, Johansson I, Dahl ML: Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents. Clin. Pharmacol. Ther. 54, 606-611 (1993).
58. LLerena A, de la Rubia A, Berecz R, Dorado P: Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients. Pharmacopsychiatry 37, 69-73 (2004).
59. Someya T, Shimoda K, Suzuki Y et al.: Effect of CYP2D6 genotypes on the metabolism of haloperidol in a Japanese psychiatric population. NeuroPsychopharmacology 28, 1501-1505 (2003).
60. Linnet K, Wiborg O: Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism. Clin. Pharmacol. Ther. 60, 41-47 (1996).
61. Jerling M, Dahl ML, Aberg-Wistedt A et al.: The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol. Clin. Pharmacol. Ther. 59, 423-428 (1996).
62. Ozdemir V, Naranjo CA, Herrmann N, Reed K, Sellers EM, Kalow W: Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo. Clin. Pharmacol. Ther. 62, 334-347 (1997).
63. LLerena A, Berecz R, Dorado P, de la Rubia A: QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations. J. Psychopharmacol. 18, 189-193 (2004).
64. Berecz R, LLerena A, de la Rubia A et al.: Relationship between risperidone and 9-hydroxy-risperidone plasma concentrations and CYP2D6 enzyme activity in psychiatric patients. Pharmacopsychiatry 35, 231-234 (2002).
65. Baumann P, Meyer JW, Amey M et al.: Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline. Ther. Drug. Monit. 14, 1-8 (1992).
66. Shin JG, Soukhova N, Flockhart DA: Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro. preferential inhibition of CYP2D6. Drug Metab. Dispos. 27, 1078-1084 (1999).
67. LLerena A, Berecz R, de la Rubia A, Norberto MJ, Benitez J: Use of the mesoridazine/thioridazine ratio as a marker for CYP2D6 enzyme activity. Ther. Drug Monit. 22, 397-401 (2000).
68. Jaanson P, Marandi T, Kiivet RA et al.: Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype. Psychopharmacology 162, 67-73 (2002).
69. Caceres MC, Peñas Liedó EM, De la Rubia A, LLerena A: Increased use of second generation antipsychotic drugs: Potential relationship with schziophrenia. Eur. J. Clin. Pharmacol. (2007) (Epub ahead of print).
70. LLerena A, Kiivet RA: Fixed combinations of neuroleptics with antidepressants: potential risks and estimation of use. Br. J. Clin. Pharmacol. 37(6), 531-532 (1994).
71. Schulze TG, Schumacher J, Muller DJ, Krauss H, Alfter D, Maroldt A: Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia. Am. J. Med. Genet. 105, 498-501 (2001).
72. Tiwari AK, Deshpande SN, Rao AR, Bhatia T, Lerer B, Nimgaonkar VL: Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms. Schizophr. Res. 75, 21-26 (2005).
73. Otani K, Aoshima T: Pharmacogenetics of classical and new antipsychotic drugs. Ther. Drug Monit. 22, 118-121 (2000).
74. Spina E, Ancione M, Di Rosa AE, Meduri M, Caputi AP: Polymorphic debrisoquina oxidation and acute neuroleptic-induced adverse effects. Eur. J. Clin. Pharmacol. 42, 347-348 (1992).
75. Meyer JW, Woggon B, Baumann P et al.: Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type. Eur. J. Clin. Pharmacol. 39, 613-614 (1990).
76. Dorado P, Berecz R, Penas-Liedo EM, LLerena A: Antipsychotic drugs and QTc prolongation: the potential role of CYP2D6 genetic polymorphism. Expert Opin. Drug Metab. Toxicol. 3, 9-19 (2007).
77. LLerena A, Berecz R, de la Rubia A, Dorado P: QTc interval lengthening and debrisoquine metabolic ratio in psychiatric patients treated with oral haloperidol monotherapy. Eur. J. Clin. Pbarmacol. 58, 223-224 (2002).
78. LLerena A, Berecz R, de la Rubia A, Dorado P: QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients. J Psychopharmacol. 16, 361-364 (2002).
79. Kirchheiner J, Nickchen K, Bauer M et al.: Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Pychiatry 9, 442-473 (2004).
80. Dorado P, Caceres MC, Pozo-Guisado E, Wong ML, Licinio, J, Lierena A: Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use. Biotechniques 39, 571-574 (2005).
81. LLerena A, Berecz R, de la Rubia A, Fernandez-Saiguero P, Dorado P: Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes. Ther. Drug Monit. 23, 616-620 (2001).
82. Inada T, Senoo H, Iijima Y, Yamauchi T, Yagi G: Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patients. Psychiatr. Genet. 13, 163-168 (2003).
83. Schillevoort I, de Boer A, van der Weide J et al.: Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study. Pharmacogenetics 12, 235-240 (2002).
84. Vandel P, Haffen E, Vandel S et al.: Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes. Eur. J Clin. Pharmacol. 55, 659-665 (1999).
85. López-Torres E, Lucena MI, Vicario F, Salomón J, Dorado P, LLerena A: Genetic polymorphisms of CYP2D6, 5HTT, 5HTR1A, 5HTR2A, DR2 and DR3 genes and extrapyramidal-induced side effects during treatment with aripiprazole. Basic Clin. Pharmacol. Toxicol. 101(Suppl. 1), 51-102 (2007).
86. Pollock BG, Mulsant BH, Sweet RA et al.: Prospective cytochrome P450 phenotyping for neuroleptic treatment in dementia. Psychopharmacol. Bull. 31, 327-331 (1995).
87. Lane HY, Hu OYP, Jann MW, Deng HC, Lin HN, Chang WH: Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients. Psychiatry Res. 69, 105-111 (1997).
88. Kapitany T, Meszaros K, Lenzinger E et al.: Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Schizophr. Res. 32, 101-106 (1998).
89. Liou YJ, Wang YC, Bai YM et al.: Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology 49, 167-173 (2004).